Myeloid cells
View article: Figure S4 from JMJD6 Shapes a Pro-tumor Microenvironment via ANXA1-Dependent Macrophage Polarization in Breast Cancer
Figure S4 from JMJD6 Shapes a Pro-tumor Microenvironment via ANXA1-Dependent Macrophage Polarization in Breast Cancer Open
Jmjd6-mediated ANXA1 secretion promotes M2 macrophage differentiation in vitro and ex vivo. A) Mean fluorescence intensity (MFI) of M1 and M2 markers in BMDM differentiated into M0, M1 and M2.** p<0,001, *** means p<0,0001, **** p<0,00001 …
View article: Supplementary Fig. 8 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Supplementary Fig. 8 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia Open
Combined FLT3/LSD1 inhibition does not substantially alter myeloid differentiation.
View article: Supplementary Figure 10 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
Supplementary Figure 10 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade Open
JQ-1 treatment in vivo increases PD-L1 expression on myeloid suppressive cells.
View article: Supplementary Fig. 11 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Supplementary Fig. 11 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia Open
Single cell ATAC-seq cell population dynamics in primary patient samples follow-ing treatment with dual FLT3/LSD1 inhibition.
View article: Supplementary Table 15 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Supplementary Table 15 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia Open
Log2 Normalized Counts of Differentially Expressed Genes from Primary AML Blast Bulk RNA-seq (24 Hours After Drug Treatment)
View article: Supplementary Fig. 12 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Supplementary Fig. 12 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia Open
Dual FLT3/LSD1 inhibition disrupts LSC clonogenicity.
View article: Supplementary Table 10 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Supplementary Table 10 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia Open
Correlation of Regulon Enrichment Signatures with MYC Gene Expression in Primary AML
View article: Supplementary Table 1 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Supplementary Table 1 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia Open
Log2 Normalized Counts of Differentially Expressed Genes from MOLM13 Bulk RNA-seq (24 Hours After Drug Treatment)
View article: Characterization of Ty21a immunostimulatory effects in the mouse bladder
Characterization of Ty21a immunostimulatory effects in the mouse bladder Open
Intravesical treatment with Salmonella enterica Ty21a, an oral typhoid-fever vaccine, has shown therapeutic potential against bladder tumors mainly through local immune-cell recruitment, particularly CD8 + T-cells. However, the mechanisms …
View article: Myeloid GPSM1 regulates atherosclerosis progression by governing monocyte and macrophage activation and chemotaxis
Myeloid GPSM1 regulates atherosclerosis progression by governing monocyte and macrophage activation and chemotaxis Open
The activation of blood monocytes and the infiltration of monocyte-derived macrophages into the vessel walls are the central part of atherosclerosis. However, the mechanisms underlying the processes remain unclear. Here, we report that G-p…
View article: Supplementary Data from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Supplementary Data from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance Open
Supplementary Figure Legends
View article: Sexual dimorphism in zymosan-induced arthritis is linked with a higher IFN response in myeloid cell subsets that faithfully recapitulate RA synovial cell clusters
Sexual dimorphism in zymosan-induced arthritis is linked with a higher IFN response in myeloid cell subsets that faithfully recapitulate RA synovial cell clusters Open
A key feature of rheumatoid arthritis (RA) is sexual dimorphism, with a higher incidence of RA in females. Myeloid cells are key drivers of the inflammatory effector phase of RA, but little is known about their contribution to a sexually d…
View article: Plasma Fibronectin Drives Macrophage Elongation via Integrin β3–Tie2 Axis in Blood Clots
Plasma Fibronectin Drives Macrophage Elongation via Integrin β3–Tie2 Axis in Blood Clots Open
Background/Objectives: Plasma fibronectin (pFN) supports lung metastasis by promoting tumor cell invasion and survival in the context of blood clotting. Here, we set out to test if myeloid cells reiterate the clot-invasive mechanisms that …
View article: Supplementary Figures from Single-Cell Profiling of CD8<sup>+</sup> T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion
Supplementary Figures from Single-Cell Profiling of CD8<sup>+</sup> T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion Open
All Supplementary Figures
View article: Figure S3 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Figure S3 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance Open
Supplementary Figure S3. Anti-VISTA-induced changes to tumor-infiltrating immune cells in MB49. B6 mice were injected intra-dermally with 100k MB49 cells and treated when tumors reached a size of 100mm3 with isotype (I) or anti-VISTA (V). …
View article: Figure S1 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Figure S1 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance Open
Quality control and cluster identification of CD45-enriched scRNAseq data. In the I/V model, BALB/c mice were administered 100k CT26 cells and treated when tumors reached a size of 40mm3 with isotype (I) or anti-VISTA (V). In the CPV model…
View article: Figure S2 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Figure S2 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance Open
Additional data supporting Figure 3. (A) Pathway enrichment for each cluster described in figure 3. (B) Comparison of myeloid clusters from this study with those identified by [30]. Dots represent the proportion of myeloid clusters describ…
View article: Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Open
Effects on STAT phosphorylation following ex vivo exposure of pre-treatment patient myeloblasts to merestinib and LY2874455. Changes in pSTAT3 and pSTAT5 after drug treatment were measured by phospho-flow cytometry and normalized to vehicl…
View article: Supplementary Figure 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Supplementary Figure 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience Open
Commutation plot visualizing the mutated genes in t-MN after OC according to PARPi treatment.
View article: Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Open
Study design.
View article: Supplementary Table S4 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
Supplementary Table S4 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer Open
Supplementary Table S4. Cluster marker genes of the Myeloid cell populations.
View article: Table S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Table S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Open
Representativeness of Study Participants
View article: Supplementary Table 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Supplementary Table 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience Open
TP53 mutations characteristics among t-MN PARPi national cohort.
View article: Supplementary Table S1 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
Supplementary Table S1 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies Open
Study population representation table
View article: Bruton Tyrosine Kinase Inhibition Limits Multiple Sclerosis Disease–Driving Inflammation While Promoting Regulatory B Cells
Bruton Tyrosine Kinase Inhibition Limits Multiple Sclerosis Disease–Driving Inflammation While Promoting Regulatory B Cells Open
These findings highlight the potential of BTK inhibition as a selective and sustainable immunomodulatory strategy for both B cells and myeloid cells in the context of chronic CNS inflammation. Despite their efficacy, broad-spectrum immunos…
View article: Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Open
Survival outcomes for the overall cohort. A, Progression-free survival. B, Overall survival.
View article: Supplementary Table 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Supplementary Table 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience Open
Patient characteristics of the national cohort according to the type of PARPi received (olaparib vs. other PARP inhibitors).
View article: Table S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Table S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Open
Patient disposition.
View article: Supplementary Figure S11 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
Supplementary Figure S11 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer Open
Supplementary Figure S11: ICI-resistant BCCs harbor higher levels of TME2-like CAFs and myeloid cells.
View article: Supplementary Table 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Supplementary Table 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience Open
Univariate analysis for overall survival from t-MN diagnosis of patients diagnosed with t-MN after OC according to PARPi exposure.